Solasia Pharma KK (FRA:9SO) E10: €-0.09 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9SO Solasia Pharma KK FRA:9SO
50 GF Score
Price €0.12
GF Value €0.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Solasia Pharma KK E10?

Solasia Pharma KK FRA:9SO +4.31% 50 E10 is €-0.09 as of Mar. 2026. GuruFocus rates FRA:9SO with a GF Score™ of 50/100 and a GF Value™ of €0.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Solasia Pharma KK's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.006. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.09 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-14), Solasia Pharma KK's current stock price is €0.121. Solasia Pharma KK's E10 for the quarter that ended in Mar. 2026 was €-0.09. Solasia Pharma KK's Shiller PE Ratio of today is .


Solasia Pharma KK  (FRA:9SO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Solasia Pharma KK E10 Related Terms


Solasia Pharma KK E10 Historical Data

* Premium members only.

The historical data trend for Solasia Pharma KK's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solasia Pharma KK E10 Chart

Solasia Pharma KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Solasia Pharma KK Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.10 0.00 0.00 -0.09

FRA:9SO vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solasia Pharma KK Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Solasia Pharma KK's Shiller PE Ratio falls into.


FRA:9SO
50GF Score
Solasia Pharma KK FRA:9SO
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solasia Pharma KK E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Solasia Pharma KK's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.006/112.7000*112.7000
=-0.006

Current CPI (Mar. 2026) = 112.7000.

Solasia Pharma KK Quarterly Data

per share eps CPI Adj_EPS
201603 -0.012 97.900 -0.014
201606 -0.041 98.100 -0.047
201609 -0.042 98.000 -0.048
201612 -0.002 98.400 -0.002
201703 -0.030 98.100 -0.034
201706 -0.028 98.500 -0.032
201709 0.011 98.800 0.013
201712 -0.053 99.400 -0.060
201803 -0.028 99.200 -0.032
201806 -0.053 99.200 -0.060
201809 -0.051 99.900 -0.058
201812 -0.069 99.700 -0.078
201903 -0.043 99.700 -0.049
201906 -0.042 99.800 -0.047
201909 -0.047 100.100 -0.053
201912 -0.015 100.500 -0.017
202003 -0.038 100.300 -0.043
202006 -0.052 99.900 -0.059
202009 -0.046 99.900 -0.052
202012 -0.147 99.300 -0.167
202103 -0.040 99.900 -0.045
202106 -0.043 99.500 -0.049
202109 -0.042 100.100 -0.047
202112 -0.021 100.100 -0.024
202203 -0.035 101.100 -0.039
202206 -0.031 101.800 -0.034
202209 -0.035 103.100 -0.038
202212 -0.020 104.100 -0.022
202303 -0.010 104.400 -0.011
202306 -0.008 105.200 -0.009
202309 -0.012 106.200 -0.013
202312 -0.013 106.800 -0.014
202403 -0.011 107.200 -0.012
202406 -0.009 108.200 -0.009
202412 0.000 110.700 0.000
202503 -0.008 111.100 -0.008
202506 -0.007 111.700 -0.007
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000
202603 -0.006 112.700 -0.006

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.09 mean?
Solasia Pharma KK (FRA:9SO) has a E10 of €-0.09 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Solasia Pharma KK and its competitors.
Is Solasia Pharma KK's E10 too high?
Solasia Pharma KK's current E10 is €-0.09. Overall, Solasia Pharma KK has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's E10 compare to ZTS and UTHR?
Solasia Pharma KK's E10 of €-0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Solasia Pharma KK and its competitors. Solasia Pharma KK's current E10 is €-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (FRA:9SO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.12 — trading 1110% above its estimated fair value. The current E10 is €-0.09. Solasia Pharma KK's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Solasia Pharma KK (FRA:9SO), the current E10 is €-0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solasia Pharma KK (FRA:9SO) Overvalued in 2026?

Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued. The current stock price of €0.12 is trading 1110% above its estimated GF Value™ of €0.01. GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.

Key valuation signals for FRA:9SO:

  • E10: €-0.09
  • GF Value™: €0.01 vs. price of €0.12 (1110% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Solasia Pharma KK Business Description

Other Exchanges 4597:Japan
Address 2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.
50GF Score

Get the complete analysis for FRA:9SO

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.01
GF Value